Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Lexicon Initiates Phase 2 Clinical Trial Of LX2931 In Patients With Rheumatoid Arthritis
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced that it has initiated a Phase 2 clinical trial of LX2931 in patients with rheumatoid arthritis. LX2931 is an orally-delivered, small molecule drug candidate that has recently completed Phase 1 testing in normal volunteers. Lexicon also successfully completed a drug-drug interaction (DDI) study of LX2931 with methotrexate in patients with rheumatoid arthritis, with no clinically significant drug-drug interactions observed.

Baylor Dallas Opens Nation's First Neurosurgical OR Suite Featuring BrainSUITE IMRI, GE Healthcare MR Surgical Technology
Baylor University Medical Center at Dallas is the first hospital in the country to collaborate with GE Healthcare and BrainLAB to open technically advanced neurosurgery operating room (OR) suites that will allow neurosurgeons to use real-time, intra-operative images of the brain during surgery. The $16.5 million operating suites will be the first to combine the BrainSUITE(R) iMRI and GE Healthcare MR Surgical Suite.
News of the day
FDA Grants Approval For Use Of RISPERDAL(R) CONSTA(R) As Both A Monotherapy And Adjunctive Therapy In The Maintenance Treatment Of Bipolar I Disorder
Janssen(R), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) has approved the Supplemental New Drug Applications (sNDAs) for the use of RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Treatment as both monotherapy and adjunctive therapy to lithium or valproate in the maintenance treatment of Bipolar I Disorder.
Oncology

Link Between Depression, Suicidal Thoughts and Later Parental-Mandated Bedtimes For Teens

Earlier parental-mandated bedtimes could help protect teens from depression and suicidal thoughts by lengthening sleep duration, according to a research abstract presented at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies. The study by James Gangwisch, PhD, of Columbia University in New York, examined data from 15,659 adolescents. A total of 1,143 teens (7.3 percent) suffered from depression and 2,038 (13 percent) had suicidal thoughts. Adolescents with parental-mandated bedtimes at midnight or later were 25 percent more likely to suffer from depression and 20 percent more likely to have suicidal ideation compared with adolescents who had parental-mandated bedtimes of 10 p.m. or earlier. "It is a common perception and societal expectation that adolescents do not need as much sleep as preadolescents, yet studies suggests that adolescents may actually require more sleep," said Gangwisch. "Studies have found that adolescents do not go to bed early enough to compensate for earlier school start times, and transitions to earlier school start times have been shown to be associated with significant sleep deprivation." According to Gangwisch, the study supports the argument that inadequate sleep could lead to depression. "Adolescents with later parental-mandated bedtimes went to bed later, got less sleep, and were less likely to get enough sleep. Short sleep duration explained the relationship between parental-mandated bedtimes and depression, functioning as a risk factor for depression and suicidal ideation." Abstract Title: Earlier Parental Mandated Bedtimes for Adolescents as a Protective Factor against Depression and Suicidal Ideation as Mediated by Sleep Duration Presentation Date: Tuesday, June 9 Category: Sleep in Psychiatric Disorders Abstract ID: 1064 Kelly Wagner American Academy of Sleep Medicine


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009